Biosimilar Manufacturer Reliability Is Key To Market Uptake, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In its latest biosimilar trends report, Amgen makes the case for purchasing biosimilars from a company with a track record for quality biologics manufacturing – presumably, one such as its own.
You may also be interested in...
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Switching, manufacturing, and indication extrapolation among worries raised in closed-door session where AbbVie argued Humira's mechanism of action is not entirely understood.
Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting
Switching, manufacturing, and indication extrapolation among worries raised in closed-door session where AbbVie argued Humira's mechanism of action is not entirely understood.
Drug Shortage Analysis Puts FDA At Loggerheads With GAO
GAO says ongoing drug shortages are increasing, but FDA says they are flattening; contrasting definitions of “shortage” produce the disparate results.